These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 27096762)

  • 21. Innovative Pharmacological Therapies for the Hemophilias Not Based on Deficient Factor Replacement.
    Mannucci PM; Mancuso ME; Santagostino E; Franchini M
    Semin Thromb Hemost; 2016 Jul; 42(5):526-32. PubMed ID: 27148843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. rFVIIIFC for hemophilia A prophylaxis.
    Mahlangu J
    Expert Rev Hematol; 2018 Dec; 11(12):937-943. PubMed ID: 30449223
    [No Abstract]   [Full Text] [Related]  

  • 23. Eloctate for hemophilia A.
    Med Lett Drugs Ther; 2015 Oct; 57(1479):143-4. PubMed ID: 26445206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring of modified factor VIII and IX products.
    Kitchen S; Gray E; Mertens K
    Haemophilia; 2014 May; 20 Suppl 4():36-42. PubMed ID: 24762273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of secondary prophylaxis in children with severe hemophilia.
    Manco-Johnson MJ; Nuss R; Geraghty S; Funk S; Kilcoyne R
    Am J Hematol; 1994 Oct; 47(2):113-7. PubMed ID: 8092125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia.
    Morfini M; Farrugia A
    Expert Rev Hematol; 2019 Oct; 12(10):883-892. PubMed ID: 31314609
    [No Abstract]   [Full Text] [Related]  

  • 27. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.
    von Mackensen S; Kalnins W; Krucker J; Weiss J; Miesbach W; Albisetti M; Pabinger I; Oldenburg J
    Haemophilia; 2017 Jul; 23(4):566-574. PubMed ID: 28370896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.
    Ragni MV
    Drugs; 2015 Sep; 75(14):1587-600. PubMed ID: 26310188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant FIXFc: a novel therapy for the royal disease?
    Valentino LA
    Expert Opin Biol Ther; 2011 Oct; 11(10):1361-8. PubMed ID: 21780945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.
    Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
    J Med Econ; 2017 Apr; 20(4):337-344. PubMed ID: 27885871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary prophylaxis in haemophilia care: Guideline update 2016.
    Fischer K; Ljung R
    Blood Cells Mol Dis; 2017 Sep; 67():81-85. PubMed ID: 28302350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.
    Björkman S
    Haemophilia; 2003 May; 9 Suppl 1():101-8; discussion 109-10. PubMed ID: 12709045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin.
    Metzner HJ; Pipe SW; Weimer T; Schulte S
    Thromb Haemost; 2013 Nov; 110(5):931-9. PubMed ID: 24178510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging drugs for hemophilia B.
    Mannucci PM; Franchini M
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):407-14. PubMed ID: 25098797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments.
    Bowyer AE; Gosselin RC
    Semin Thromb Hemost; 2023 Sep; 49(6):609-620. PubMed ID: 36473488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.
    Oldenburg J; Hay CRM; Jiménez-Yuste V; Peyvandi F; Schved JF; Szamosi J; Winding B; Lethagen S
    BMJ Open; 2019 May; 9(5):e028012. PubMed ID: 31152037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factor VIII therapy for hemophilia A: current and future issues.
    Aledort L; Ljung R; Mann K; Pipe S
    Expert Rev Hematol; 2014 Jun; 7(3):373-85. PubMed ID: 24717090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylactic Treatment of Children with Hemophilia in Sweden.
    Ljung R
    Semin Thromb Hemost; 2024 Jul; 50(5):714-719. PubMed ID: 38499191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
    Collins P; Chalmers E; Chowdary P; Keeling D; Mathias M; O'Donnell J; Pasi KJ; Rangarajan S; Thomas A
    Haemophilia; 2016 Jul; 22(4):487-98. PubMed ID: 27311929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.